Clinical Trials in Austria

• A study of Navenibart in Participants with Hereditary Angioedema Ended
  2025-521660-35-00 Phase III Hereditary Angioedema Astria Therapeutics Inc.
• A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor Neuropathy Ended
  2024-516473-72-00 Phase III Multifocal Motor Neuropathy Argenx
• Rezafungin for treatment of chronic pulmonary aspergillosis (CPA) in adults with limited treatment options Ended
  2024-519575-26-00 Phase II Chronic pulmonary aspergillosis (CPA) Mundipharma Research Limited
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended
  2024-518998-33-00 Phase III Ulcerative Colitis AbbVie Deutschland GmbH & Co. KG
• A Study to Evaluate Tobevibart+Elebsiran in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide Ended
  2024-519282-22-00 Phase III Chronic Hepatitis D Virus (HDV) Infection Vir Biotechnology Inc.
• Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended
  2024-517817-34-00 Phase I/II Gastric Cancer Merck Healthcare KGaA
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended
  2024-513266-19-00 Phase III Hidradenitis Suppurativa (HS) Novartis Pharma AG
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended
  2024-517818-15-00 Phase I/II Non-Small Cell Lung Cancer Merck Healthcare KGaA
• A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr… Ended
  2024-511754-41-00 Phase II idiopathic pulmonary fibrosis Endeavor Biomedicines Inc.
• A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced… Ended
  2024-512504-19-00 Phase I solid tumors Boehringer Ingelheim International GmbH
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Ended
  2024-517422-25-00 Phase III Metastatic Castration-resistant Prostate Cancer (mCRPC) Celgene Corp.
• A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti­IL­33 mAb) in participants with inadequately-controlled… Ended
  2024-516814-39-00 Phase III Chronic rhinosinusitis with nasal polyps Sanofi-Aventis Recherche & Developpement
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended
  2024-513968-25-00 Phase III Metastatic castration-resistant prostate cancer (mCRPC) Amgen Inc.
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended
  2024-516609-22-00 Phase III Primary Sjögren’s Disease Argenx
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L… Ended
  2022-501489-24-00 Phase III First-line treatment of adult subjects with high-risk large … Kite Pharma Inc.
• BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended
  2024-515740-23-00 Phase III Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Bristol-Myers Squibb Services Unlimited Company
• An Open-label study of patients with primary sclerosing cholangitis (PSC) treated with norucholic acid tablets Ended
  2024-514292-18-00 Phase III Primary Sclerosing Cholangitis (PSC) Dr. Falk Pharma GmbH
• A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravis Ended
  2024-514133-38-00 Phase III Ocular Myasthenia Gravis Argenx
• A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma Ended
  2024-513738-39-00 Phase I/II IDH1-mutant Glioma Institut De Recherches Internationales Servier IRIS
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole… Ended
  2024-514594-21-00 Phase III Heterozygous Familial Hypercholesterolemia Novartis Pharma AG
• A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration… Ended
  2024-515022-88-00 Phase III Dry Age-Related Macular Degeneration (AMD) with geographic a… Annexon Inc.
• AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protoco… Ended
  2024-511253-21-00 Phase I (Other) Thoracic tumors with homozygous MTAP-deletion Amgen Inc.
• A Phase 3 Study of Brepocitinib in Adults with Active, Non-Infectious, Non-Anterior Uveitis (CLARITY) Ended
  2024-515089-15-00 Phase III active non-infectious uveitis (intermediate uveitis, posteri… Priovant Therapeutics Inc.
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended
  2024-512998-27-00 Phase III Non-Small Cell Lung Cancer Genmab A/S

Showing 553–576 of 1,115 trials